Myriad Genetics, Inc. (MYGN)
- Previous Close
26.23 - Open
26.40 - Bid 26.44 x 100
- Ask 26.51 x 100
- Day's Range
26.23 - 26.95 - 52 Week Range
13.82 - 29.30 - Volume
193,375 - Avg. Volume
760,403 - Market Cap (intraday)
2.403B - Beta (5Y Monthly) 1.92
- PE Ratio (TTM)
-- - EPS (TTM)
-1.77 - Earnings Date Nov 4, 2024 - Nov 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
29.93
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
www.myriad.com2,700
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MYGN
View MorePerformance Overview: MYGN
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MYGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MYGN
View MoreValuation Measures
Market Cap
2.38B
Enterprise Value
2.43B
Trailing P/E
--
Forward P/E
434.78
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.85
Price/Book (mrq)
3.22
Enterprise Value/Revenue
3.03
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-19.35%
Return on Assets (ttm)
-5.68%
Return on Equity (ttm)
-21.03%
Revenue (ttm)
802.2M
Net Income Avi to Common (ttm)
-155.2M
Diluted EPS (ttm)
-1.77
Balance Sheet and Cash Flow
Total Cash (mrq)
97.3M
Total Debt/Equity (mrq)
19.35%
Levered Free Cash Flow (ttm)
-102.36M